Strategic priorities for respiratory syncytial virus (RSV) vaccine development

Although RSV has been a high priority for vaccine development, efforts to develop a safe and effective vaccine have yet to lead to a licensed product. Clinical and epidemiologic features of RSV disease suggest there are at least 4 distinct target populations for vaccines, the RSV naïve young infant,...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, L.J., Dormitzer, P.R., Nokes, D.J., Rappuoli, R., Roca, A., Graham, B.S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3919153/
https://www.ncbi.nlm.nih.gov/pubmed/23598484
http://dx.doi.org/10.1016/j.vaccine.2012.11.106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3919153/
https://www.ncbi.nlm.nih.gov/pubmed/23598484
http://dx.doi.org/10.1016/j.vaccine.2012.11.106

Ejemplares similares